Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Kwok

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Rheumatology and Therapy|December 16, 2022
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development ProgramsKevin L Winthrop, Arne Yndestad, Dan Henrohn, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Annals of the Rheumatic Diseases|February 2, 2017
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
International Journal of Rheumatic Diseases|June 2, 2020
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 yearsArvind Chopra, Vineeta Shobha, Srikantiah Chandrashekara, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 23, 2020
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical TrialsGustavo Citera, Eduardo Mysler, Hugo Madariaga, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 2, 2017
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World PopulationOswaldo M Castañeda, Felix J Romero, Ariel Salinas, et al.
Annals of the Rheumatic Diseases|September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL SurveillanceChristina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
Annals of the Rheumatic Diseases|September 24, 2025
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular diseaseJon T Giles, Christina Charles-Schoeman, Maya H Buch, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Rheumatology and Therapy|December 16, 2022
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development ProgramsKevin L Winthrop, Arne Yndestad, Dan Henrohn, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Annals of the Rheumatic Diseases|February 2, 2017
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
International Journal of Rheumatic Diseases|June 2, 2020
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 yearsArvind Chopra, Vineeta Shobha, Srikantiah Chandrashekara, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 23, 2020
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical TrialsGustavo Citera, Eduardo Mysler, Hugo Madariaga, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 2, 2017
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World PopulationOswaldo M Castañeda, Felix J Romero, Ariel Salinas, et al.
Annals of the Rheumatic Diseases|September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL SurveillanceChristina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
Annals of the Rheumatic Diseases|September 24, 2025
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular diseaseJon T Giles, Christina Charles-Schoeman, Maya H Buch, et al.
Pageof 6